Coronavirus Vaccine Problems News ArticlesExcerpts of key news articles on coronavirus vaccine problems
One hundred and six people who had been fully vaccinated against the coronavirus died from the disease in Massachusetts by the end of July, according to the state Department of Public Health. Six new deaths among breakthrough cases were reported Tuesday, along with more than 2,000 new cases. The department also reported 445 breakthrough hospitalizations in the state.
Note: Much of the full article at the link above greatly downplays this information. Yet Massachusetts has 7 million people or about 1/50th of the population of the US. So it is likely that somewhere around 5,000 fully vaccinated people in the US have died. Are these shots as effective as they are touted to be? And why is this getting virtually no attention in the media? For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
One remarkable aspect of the Covid-19 pandemic has been how often unpopular scientific ideas, from the lab-leak theory to the efficacy of masks, were initially dismissed, even ridiculed, only to resurface later. Another reversal in thinking may be imminent. Some scientists have raised concerns that the safety risks of Covid-19 vaccines have been underestimated. But the politics of vaccination has relegated their concerns to the outskirts of scientific thinking. The Vaccine Adverse Event Reporting System, or Vaers ... is a database that allows Americans to document adverse events that occur after receiving a vaccine. Vaers data for Covid-19 vaccines shows an interesting pattern. Among the 310 million Covid-19 vaccines administered, several adverse events are reported at high rates in the days immediately following vaccination, then drop sharply thereafter. The silence around these potential signals of harm reflects the policy surrounding Covid-19 vaccines. The stigma of such concerns is bad for scientific integrity and could harm patients. Four serious adverse events follow this arc, according to data directly from Vaers: low platelet count (thrombocytopenia); non-infectious myocarditis or inflammation of the heart, especially in those under 30; deep vein thrombosis. The implication is that the risks of a Covid-19 vaccine may outweigh the benefits for some low-risk populations, such as children, young adults, and people who have recovered from Covid-19.
Note: This article is also available here. Read a revealing article on how the WHO is flip flopping on the safety of vaccines for children. For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
AstraZeneca may have included "outdated information" in touting the effectiveness of its COVID-19 vaccine in a U.S. study, federal health officials said Tuesday in an unusual public rift that could further erode confidence in the shot. In an extraordinary rebuke, just hours after AstraZeneca on Monday announced its vaccine worked well in the U.S. study, an independent panel that oversees the study scolded the company for cherry-picking data, according to a senior administration official. The panel wrote to AstraZeneca and U.S. health leaders that it was concerned the company chose to use data that was outdated and potentially misleading instead of the most recent and complete findings. The NIH's Dr. Anthony Fauci told ABC's "Good Morning America" that the incident "really is what you call an unforced error" and that he expects the discrepancy to be straightened out. But that nitty-gritty seldom is seen by the public, something now exposed by the extraordinary microscope being applied to development of the world's COVID-19 vaccines. The vaccine is used widely in Britain, across the European continent and in other countries, but its rollout was troubled by inconsistent study reports about its effectiveness, and then last week a scare about blood clots that had some countries temporarily pausing inoculations. Company executives refused repeated requests from reporters to provide a breakdown of the 141 COVID-19 cases it was using to make the case for the shot's effectiveness.
Note: For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
As the new Coronavirus spreads illness, death, and catastrophe around the world, virtually no economic sector has been spared from harm. Yet amid the mayhem ... one industry is not only surviving, it is profiting handsomely. "Pharmaceutical companies view Covid-19 as a once-in-a-lifetime business opportunity," said Gerald Posner, author of "Pharma: Greed, Lies, and the Poisoning of America." The world needs ... treatments and vaccines and, in the U.S., tests. Dozens of companies are now vying to make them. The ability to make money off of pharmaceuticals is already uniquely large in the U.S., which lacks the basic price controls other countries have, giving drug companies more freedom over setting prices for their products than anywhere else in the world. During the current crisis, pharmaceutical makers may have even more leeway than usual because of language industry lobbyists inserted into an $8.3 billion coronavirus spending package, passed last week, to maximize their profits from the pandemic. Initially, some lawmakers had tried to ensure that the federal government would limit how much pharmaceutical companies could reap from vaccines and treatments for the new coronavirus that they developed with the use of public funding. But many Republicans opposed adding language to the bill that would restrict the industry's ability to profit, arguing that it would stifle research and innovation. The final aid package not only omitted language that would have limited drug makers' intellectual property rights, it specifically prohibited the federal government from taking any action if it has concerns that the treatments or vaccines developed with public funds are priced too high.
Note: For glaring examples of how big Pharma and select public officials made money hand over fist during previous virus scares, see concise summaries of deeply revealing news articles on the avian and swine flu from reliable major media sources.
The goal of this project is to improve the quality of vaccination programs by improving the quality of physician adverse vaccine event detection and reporting to the national Vaccine Adverse Event Reporting System (VAERS). Restructuring at CDC and consequent delays in terms of decision making have made it challenging despite best efforts to move forward. Adverse events from drugs and vaccines are common, but underreported. Although 25% of ambulatory patients experience an adverse drug event, less than 0.3% of all adverse drug events and 1-13% of serious events are reported to the Food and Drug Administration (FDA). Likewise, fewer than 1% of vaccine adverse events are reported. Low reporting rates preclude or slow the identification of "problem" drugs and vaccines that endanger public health. New surveillance methods for drug and vaccine adverse effects are needed. Barriers to reporting include a lack of clinician awareness, uncertainty about when and what to report, as well as the burdens of reporting: reporting is not part of clinicians' usual workflow, takes time, and is duplicative. Unfortunately, there was never an opportunity to perform system performance assessments because the necessary CDC contacts were no longer available and the CDC consultants responsible for receiving data were no longer responsive to our multiple requests to proceed with testing and evaluation.
Note: The U.S. government here is admitting that less than 1% of vaccine injuries are reported. What does this say about the safety of vaccines in general? For more along these lines, see concise summaries of deeply revealing news articles on vaccines from reliable major media sources.
In India – where the Delta variant was first identified and caused a huge outbreak – cases have plunged over the past two months. A similar drop may now be underway in Britain. There is no clear explanation for these declines. In the U.S., cases started falling rapidly in early January. The decline began before vaccination was widespread and did not follow any evident changes in Americans' Covid attitudes. This spring, caseloads were not consistently higher in parts of the U.S. that had relaxed masking and social distancing measures (like Florida and Texas) than in regions that remained vigilant. Large parts of Africa and Asia still have not experienced outbreaks as big as those in Europe, North America and South America. How do we solve these mysteries? Michael Osterholm, who runs an infectious disease research center at the University of Minnesota, suggests that ... Americans should not assume that Delta is destined to cause months of rising caseloads. Nor should they assume that a sudden decline, if one starts this summer, fits a tidy narrative that attributes the turnaround to rising vaccination and mask wearing. We are certainly not powerless in the face of Covid. We can reduce its risks, just as we can reduce the risks from driving, biking, swimming and many other everyday activities. But we cannot eliminate them. "We're not in nearly as much control as we think are," Osterholm said.
Note: For strong evidence that Ivermectin use is one significant cause of the major drop in India, see this webpage. And Sweden, which was hit hard in the beginning of the pandemic yet has never instituted a lockdown or mandated masks, is doing better than the U.S. and most European countries. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus from reliable major media sources.
Scientists who studied a big COVID-19 outbreak in Massachusetts concluded that vaccinated people who got so-called breakthrough infections carried about the same amount of the coronavirus as those who did not get the shots. Health officials on Friday released details of that research, which was key in this week's decision by the Centers for Disease Control and Prevention to recommend that vaccinated people return to wearing masks indoors. The authors said the findings suggest the CDC's mask guidance should be expanded to include the entire country, even outside of hot spots. The findings have the potential to upend past thinking about how the disease is spread. Previously, vaccinated people who got infected were thought to have low levels of virus and to be unlikely to pass it to others. But the new data shows that is not the case with the delta variant. The outbreak in Provincetown – a seaside tourist spot on Cape Cod in the county with Massachusetts' highest vaccination rate – has so far included more than 900 cases. About three-quarters of them were people who were fully vaccinated. Leaked internal documents ... suggest the CDC may be considering other changes in advice on how the nation fights the coronavirus, such as recommending masks for everyone and requiring vaccines for doctors and other health workers. People with breakthrough infections make up an increasing portion of hospitalizations and in-hospital deaths among COVID-19 patients.
Note: Read also about a surge in reports of serious injuries after receiving COVID injections. For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
The cost of vaccinating the world against COVID-19 could be at least five times cheaper if pharmaceutical companies weren't profiteering from their monopolies on COVID-19 vaccines, campaigners from The People's Vaccine Alliance said today. New analysis by the Alliance shows that the firms Pfizer/BioNTech and Moderna are charging governments as much as $41 billion above the estimated cost of production. Colombia, for example, has potentially overpaid by as much as $375 million for its doses of the Pfizer/BioNTech and Moderna vaccines, in comparison to the estimated cost price. Despite a rapid rise in COVID cases and deaths across the developing world, Pfizer/BioNTech and Moderna have sold over 90 percent of their vaccines so far to rich countries, charging up to 24 times the potential cost of production. Neither company have agreed to fully transfer vaccine technology and know-how with any capable producers in developing countries, a move that could increase global supply, drive down prices and save millions of lives. Analysis of production techniques for the leading mRNA type vaccines produced by Pfizer/BioNTech and Moderna â€•which were only developed thanks to public funding to the tune of $8.3 billionâ€• suggest these vaccines could be made for as little as $1.20 a dose. Yet COVAX, the scheme set up to help countries get access to COVID vaccines, has been paying, on average, nearly five times more.
Pfizer expects to sell $15 billion worth of Covid-19 vaccines in 2021. That would make it the second-highest revenue-generating drug anytime, anywhere, according to industry reports. The maker of the first Covid-19 vaccine to be approved for use in advanced markets has released its earning forecasts for 2021 today. Pfizer expects to earn between $59 billion and $61 billion - up from $42 billion it made in 2020. Sales of the vaccine are set to bring in about a fourth of Pfizer's total revenue this year. That would be nearly as much as its three best-selling products combined. The company is expecting profit margins for the vaccine to be between 25% and 30% which means profits from the vaccine could be around $4 billion. All of Pfizer's costs and profits from the vaccine are split evenly with BioNTech, the biotech company that helped develop the treatment. There are is only one drug in the world that sells more - Humira, a prescription medication for arthritis. Pfizer plans on selling 2 billion doses of the vaccine this year, but that demand should subside in coming years so the revenue of Covid-19 vaccine won't be stable, Pfizer's CEO Albert Bourla said on an call with analysts and investors. The company expects to continue profiting from it by selling booster doses, including ones required to shield against new variants of the virus, Bourla said. Further, Pfizer is pursuing more avenues to employ the mRNA technology underlying the vaccine, including a flu vaccine and other therapeutic applications.
Note: Read more in this revealing Reuters article. For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines and Big Pharma profiteering from reliable major media sources.
A tremendous number of government and private policies affecting kids are based on one number: 335. That is how many children under 18 have died with a Covid diagnosis code in their medical record, according to the Centers for Disease Control and Prevention. Yet the CDC, which has 21,000 employees, hasn't researched each death to find out whether Covid caused it or if it involved a pre-existing medical condition. Without these data, the CDC Advisory Committee on Immunization Practices decided in May that the benefits of two-dose vaccination outweigh the risks for all kids 12 to 15. I've written hundreds of peer-reviewed medical studies, and I can think of no journal editor who would accept the claim that 335 deaths resulted from a virus without data to indicate if the virus was incidental or causal. Johns Hopkins worked with the nonprofit FAIR Health to analyze approximately 48,000 children under 18 diagnosed with Covid in health-insurance data. Our report found a mortality rate of zero among children without a pre-existing medical condition. The National Education Association has been debating whether to urge schools to require vaccination before returning to school in person. How can they or anyone debate the issue without the right data? Meanwhile ... Alameda County, Calif., reduced its Covid death toll by 25%. after state public-health officials insisted that deaths be attributed to Covid only if the virus was a direct or contributing factor
Note: Alameda County corrected their COVID death figures, but how many other counties throughout the US did not? If you can't access this article on the WSJ website, go to this webpage. For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
In the coming months, Linda Thomas-Greenfield, President Joe Biden's ambassador to the United Nations, will hear from a growing chorus of developing nations about the foundering efforts to distribute the coronavirus vaccine globally. The nations, many of which have not even begun vaccinating their populations, are demanding that the U.S. support proposals to temporarily waive certain patent and intellectual property rights so that generic coronavirus vaccines can be produced. The proposals have been fiercely opposed by American drugmakers, including Pfizer. ASG ... represents Pfizer. Many leading figures in Biden's administration, including key White House advisers, State Department leaders, and health care officials have financial stake in or professional ties to vaccine manufacturers, which are now lobbying to prevent policies that would cut into future profits over the vaccine. ASG in particular has unusual amounts of sway in the Biden administration. State Department officials Victoria Nuland, Wendy Sherman, Uzra Zeya, and Molly Montgomery previously worked at ASG, as did Philip Gordon, Vice President Kamala Harris's national security adviser. The pharmaceutical industry, in a bid to shield an expected financial windfall, has pressed the Biden administration not only to oppose the waiver, but also to impose trade-related sanctions on countries that back [a] proposal or move to manufacture coronavirus vaccines without permission from patent holders.
A four-inch wafer of silicon has been turned into an army of one million microscopic, walking robots, thanks to some clever engineering employed by researchers at Cornell University in New York. In a paper, published Wednesday in the journal Nature, a team of roboticists detail the creation of their invisible army of robots, which are less than 0.1mm in size (about the width of a human hair) and cannot be seen with the naked eye. The robots ... take advantage of an innovative, new class of actuators, which are the legs of the microrobots. Controlling movement in these tiny machines requires the researchers to shine a laser on minuscule light-sensitive circuits on their backs, which propels their four legs forward. They've been designed to operate in all manner of environments such as extreme acidity and temperatures. One of their chief purposes, the researchers say, could be to investigate the human body from the inside. The team was able to build incredibly small legs, which are connected to two different patches on the back of the robot - one for the front pair of legs, one for the back. Alternating light between the patches propels the microrobot forward. The research team were able to show the microrobots devices could fit within the narrowest hypodermic needle and thus, could be "injected" into the body. The machines aren't intelligent enough to target a diseased cell or respond to stimuli, so there's no application for this invisible army. However, the researchers said that "their capabilities can rapidly evolve."
Note: Remember that secret military projects are often 20 years or more advanced of anything made public. Could this technology have already been developed in secret projects and used in military vaccines? Yale professor Charles Morgan describes in this two-minute video (or this one) how cells injected through hypodermic needles can cause foreign substances to be manufactured in our bodies, how they can alter a person's memory, and much more. His full presentation on psycho-neurobiology and war given at West Point Military Academy is quite disturbing.
Pfizer chairman Albert Bourla told NBC's Dateline host Lester Holt that the pharmaceutical company was "not certain" if the vaccine prevented the coronavirus from being transmitted, saying: "This is something that needs to be examined." In a prime-time special titled "Race for a Vaccine" ... Holt questioned Bourla and other individuals involved in the development and distribution of the vaccine. In November, Pfizer announced that its vaccine candidate had been shown to be more than 90% effective at preventing COVID-19 and has applied for emergency use authorization from the Food and Drug Administration (FDA). The U.K. became the first country to approve Pfizer's vaccine this week with the first round of immunizations expected to roll out next week. In August, Canada signed a deal with Pfizer for 20 million doses of the vaccine. In a list of interview highlights released before the special, Holt asked Bourla: "Even though I've had the protection, am I still able to transmit it to other people?" "I think this is something that needs to be examined. We are not certain about that right now with what we know," Bourla responded.
Note: An MSN article reported that a 41-year-old Portuguese health worker died two days after getting the Pfizer vaccine, but then removed the article. Learn more about this death in this article. A Florida doctor also died after receiving the vaccine. This CDC report states "December 14–23, 2020, monitoring â€¦ detected 21 cases of anaphylaxis after administration of a reported 1,893,360 first doses of the Pfizer-BioNTech COVID-19 vaccine." For more, explore the excellent, reliable resources provided in our Coronavirus Information Center.
The pharmaceutical industry keeps turning up the dial on lobbying, setting massive new spending records in its intensive effort to influence Congress and the Biden administration. Yet this week, President Biden angered drugmakers when he said he supports the waiving of intellectual property protections for coronavirus vaccines. Drug and health product manufacturers, along with their national association, spent a combined $92 million to lobby the federal government from January through March. That puts the industry on track to break its spending record for the second year in a row. Not only that, but its first-quarter spending was more than double what was spent by the second-highest-spending industry, electronics companies. There are currently 1,270 registered lobbyists for pharmaceuticals and health products – more than two lobbyists for every member of Congress. Pfizer, maker of one of the three coronavirus vaccines approved for emergency use in the United States, was the biggest spender of any individual drug company. And last year, as it was developing its vaccine, the federal government agreed to pay the company $1.95 billion for the first 100 million doses it produced. The company reported it had $3.5 billion in revenue from sales of the vaccine so far this year. Pfizer was outflanked on lobbying spending only by the Pharmaceutical Research and Manufacturers of America – the national association that represents the interests of drugmakers.
At least four candidates are near the finish line in the U.S. coronavirus vaccine race. A key point to note, however, is that the vaccine isn't an end-all solution to the pandemic. That's in large part because any inoculations developed now are focused on simply preventing symptoms from arising, rather than blocking out the virus altogether. The latter goal is a secondary endpoint, according to Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. "The primary thing you want to do is that if people get infected, prevent them from getting sick, and if you prevent them from getting sick, you will ultimately prevent them from getting seriously ill," Fauci said. "What I would settle for, and all of my colleagues would settle for, is the primary endpoint to prevent clinically recognizable disease," he said. That level of protection would be the ultimate goal to diffusing the crisis, but is hard to do with companies facing an immediate demand for some sort of solution. While no vaccine is 100% effective, having a majority of the population inoculated and higher percentages of efficacy is the best to hope for. The U.K. is looking at challenge trials, which intentionally infect a smaller group of participants with the virus in an effort to test a vaccine's or treatment's efficacy. Fauci said the U.S. is not anticipating such a move because the rate of spread is so high in the country that it's sufficient enough of an environment to test the vaccine.
Note: This Bloomberg article further shows the vaccines are not designed to stop the virus. Why is the media not doing a better job of informing the public about this. Read also this CNBC article titled "Dr. Fauci says masks, social distancing will still be needed after a Covid-19 vaccine." For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccine issues from reliable major media sources.
Moderna, Pfizer, AstraZeneca, and Johnson & Johnson are leading candidates for the completion of a Covid-19 vaccine likely to be released in the coming months. These companies have published their vaccine trial protocols. Close inspection of the protocols raises surprising concerns. These trials seem designed to prove their vaccines work, even if the measured effects are minimal. Prevention of infection is not a criterion for success for any of these vaccines. In fact, their endpoints all require confirmed infections and all those they will include in the analysis for success, the only difference being the severity of symptoms between the vaccinated and unvaccinated. Measuring differences amongst only those infected by SARS-CoV-2 underscores the implicit conclusion that the vaccines are not expected to prevent infection, only modify symptoms of those infected. We all expect an effective vaccine to prevent serious illness if infected. Three of the vaccine protocols - Moderna, Pfizer, and AstraZeneca - do not require that their vaccine prevent serious disease only that they prevent moderate symptoms which may be as mild as cough, or headache. A vaccine must significantly or entirely reduce deaths from Covid-19. None list mortality as a critical endpoint.
Note: Read also this article in BMJ (British Medical Journal) titled "Will covid-19 vaccines save lives? Current trials aren't designed to tell us." And this CNBC article is titled "Dr. Fauci says masks, social distancing will still be needed after a Covid-19 vaccine." For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccine issues from reliable major media sources.
The announcement this week that a cheap, easy-to-make coronavirus vaccine appeared to be up to 90 percent effective was greeted with jubilation. But since unveiling the preliminary results, AstraZeneca has acknowledged a key mistake in the vaccine dosage received by some study participants, adding to questions about whether the vaccine's apparently spectacular efficacy will hold up under additional testing. Scientists and industry experts said the error and a series of other irregularities and omissions in the way AstraZeneca initially disclosed the data have eroded their confidence in the reliability of the results. The regimen that appeared to be 90 percent effective was based on participants receiving a half dose of the vaccine followed a month later by a full dose; the less effective version involved a pair of full doses. AstraZeneca disclosed in its initial announcement that fewer than 2,800 participants received the smaller dosing regimen, compared with nearly 8,900 participants who received two full doses. Moncef Slaoui, the head of Operation Warp Speed, the U.S. initiative to fast-track coronavirus vaccines, noted another limitation in AstraZeneca's data. On a call with reporters, he suggested that the participants who received the half-strength initial dose had been 55 years old or younger. The fact that the initial half-strength dose wasn't tested in older participants, who are especially vulnerable to Covid-19, could undermine AstraZeneca's case to regulators that the vaccine should be authorized for emergency use.
Note: Learn in this revealing article how vaccine trials are rigged. This article spells out how vaccine makers are above the law and face no consequences for damage from vaccines. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and vaccines from reliable major media sources.
On June 26, a small South San Francisco company called Vaxart made a surprise announcement: A coronavirus vaccine it was working on had been selected by the U.S. government to be part of Operation Warp Speed, the flagship federal initiative to quickly develop drugs to combat Covid-19. The race is on to develop a coronavirus vaccine, and some companies and investors are betting that the winners stand to earn vast profits from selling hundreds of millions – or even billions – of doses to a desperate public. Across the pharmaceutical and medical industries, senior executives and board members ... are making millions of dollars after announcing positive developments, including support from the government, in their efforts to fight Covid-19. After such announcements, insiders from at least 11 companies – most of them smaller firms whose fortunes often hinge on the success or failure of a single drug – have sold shares worth well over $1 billion since March. Senior officials appear to be pouncing on opportunities to cash out. And some companies have awarded stock options to executives shortly before market-moving announcements about their vaccine progress. Some companies are attracting government scrutiny for ... using their associations with Operation Warp Speed as marketing ploys. Vaxart's news release declared: "Vaxart's Covid-19 Vaccine Selected for the U.S. Government's Operation Warp Speed." But Vaxart is not among the companies selected to receive significant financial support from Warp Speed.
Note: MSN strangely removed this article a few days after posting it. A similar article by the New York Times titled "The race for a coronavirus vaccine is making some corporate insiders very rich" is available here. For more along these lines, see concise summaries of deeply revealing news articles on big Pharma corruption and the coronavirus from reliable major media sources.
On 28 July 2021, Pfizer and BioNTech posted updated results for their ongoing phase 3 covid-19 vaccine trial. The preprint came almost a year to the day after the historical trial commenced, and nearly four months since the companies announced vaccine efficacy estimates "up to six months.". But you won't find 10 month follow-up data here. While the preprint is new, the results it contains aren't particularly up to date. Since late last year, we've heard that Pfizer and Moderna's vaccines are "95% effective." Measuring vaccine efficacy two months after dosing says little about just how long vaccine-induced immunity will last. "Waning immunity" is a known problem for influenza vaccines, with some studies showing near zero effectiveness after just three months. And so the recent reports from Israel's Ministry of Health caught my eye. In early July, they reported that efficacy against infection and symptomatic disease "fell to 64%." By late July it had fallen to 39% where Delta is the dominant strain. This is very low. For context, the FDA's expectation is of "at least 50%" efficacy for any approvable vaccine. Now Israel, which almost exclusively used Pfizer vaccine, has begun administering a third "booster" dose to all adults over 40. The US plans to follow suit. Until new clinical trials demonstrate that boosters increase efficacy above 50%, without increasing serious adverse events, it is unclear whether the 2-dose series would even meet the FDA's approval standard at six or nine months.
Note: For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
Last spring, Israel's remarkably swift vaccination campaign was seen as a global model. Coronavirus infections plummeted, an electronic pass allowed the vaccinated to attend indoor concerts and sporting events, and distancing rules and mask mandates were eventually scrapped. Israel offered the world a hopeful glimpse of the way out of the pandemic. No longer. A fourth wave of infections is rapidly approaching the levels of Israel's worst days of the pandemic last winter. The daily rate of confirmed new virus cases has more than doubled in the last two weeks, making Israel a rising hot spot. Restrictions on gatherings and commercial and entertainment venues were reinstated this week, and the government is considering a new lockdown. Some experts fear that Israel's high rate of infections among early vaccine recipients may indicate a waning of the vaccine's protections over time. The vaccine may be less effective at preventing infection with the highly contagious Delta variant. The vast majority of Israel's older population had received two doses of the Pfizer-BioNTech vaccine by the end of February, and by now about 78 percent of the population 12 and older are fully vaccinated. Data published by Israel's Ministry of Health in late July suggested that the Pfizer shot was just 39 percent effective against preventing infection in the country in late June and early July, compared with 95 percent from January to early April.
Note: Whatever happened to the 95% efficacy of the Pfizer vaccine? For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.
Important Note: Explore our full index to revealing excerpts of key major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.